Core Insights - Virtual healthcare and physician-focused digital platforms are transforming U.S. healthcare delivery, with Hims & Hers Health, Inc. and Doximity, Inc. leading the charge [1][2] - Hims & Hers focuses on consumer access and affordability, while Doximity leverages its physician network and enterprise solutions [2] Stock Performance & Valuation - Hims & Hers has increased by 208.8% over the past year, outperforming Doximity's 73.4% gain, although Doximity has outperformed Hims & Hers in the last three months with a 21.8% increase compared to Hims' 11.1% [3][6] - Hims & Hers has a forward price-to-sales (P/S) ratio of 4.6, while Doximity's is at 20.9, both above their respective three-year medians [5] - Hims & Hers has a Zacks Style Score with a Growth Score of A, while Doximity has a Growth Score of B [5] Growth Drivers for Hims & Hers - Hims & Hers is diversifying its offerings into areas like weight loss and chronic conditions, with the rollout of generic semaglutide presenting a significant opportunity [7] - The company is expanding internationally, with plans to enter Canada in 2026 and the acquisition of ZAVA enhancing its European presence [7] - Hims & Hers is investing in AI to improve diagnostics and treatment personalization, aiming for a technology-driven healthcare platform [8] Growth Drivers for Doximity - Doximity has over 80% of U.S. physicians active on its platform, with high engagement levels and a sticky ecosystem that supports recurring revenue growth [10] - The launch of Doximity Scribe, which automates clinical note-taking, has seen strong adoption, with over 75% of users returning weekly [11] - Doximity's growth is supported by strong adoption among pharmaceutical and health system clients, contributing to broad-based revenue growth [12] Earnings Projections - The Zacks Consensus Estimate for Hims & Hers suggests a 122.2% improvement in earnings per share (EPS) from 2024 to 2025 [15] - Doximity's fiscal 2026 EPS is projected to improve by 6.3% from fiscal 2025 [17] Price Targets - The average price target for Hims & Hers is $48.67, indicating a potential decline of 11.3% from the last close [20] - The average price target for Doximity is $68.83, suggesting a potential increase of 7.5% from the last close [23] Investment Considerations - Hims & Hers is viewed as a more stable investment opportunity with strong profitability and user engagement, while Doximity is rapidly expanding but may be trading at a higher valuation [24][25] - Both companies are ranked 3 (Hold) by Zacks, but Hims & Hers is considered to have a more capital-efficient model and better growth prospects [24][25]
HIMS vs. DOCS: Which Digital Health Platform Is a Better Investment?